NYSE:DHRLife Sciences
Danaher (DHR) Valuation Under Review As Revenue And Margin Pressures Confront Recent Share Price Strength
Why Danaher (DHR) Is Back in Focus
Danaher (DHR) is back on investors’ radar after fresh data highlighted two years of average 1.6% organic revenue decline, shrinking margins, and a steady drop in return on invested capital, despite recent share outperformance.
See our latest analysis for Danaher.
Despite the pressure on organic revenue and margins, recent price action has been relatively firm, with a 30 day share price return of 6.16% and a 90 day share price return of 8.67%. However, the 1...